AKT1 and breast carcinoma: The pan-AKT inhibitor AZD5363 (capivasertib) was firstly approved by FDA in November 2023 for use in combination with fulvestrant to treat HR-positive/HER2-negative breast cancer, which not only validates the AKT pathway as a druggable target, but also pioneers a new paradigm in biomarker-driven precision oncology (23).